Catalent Signs Agreement With Astrazeneca To Manufacture Covid-19 Vaccine Candidate

In June, Catalent reached an agreement with AstraZeneca to provide bottling and packaging capabilities at its production site in Anagni, Italy, and to prepare for the delivery of hundreds of millions of million doses of vaccine from this month and possibly by March 2022. Catalent is working with Spicona to develop COVID-19 vaccines that use GPEx┬« Cell Line Development Platform. AstraZeneca has signed several manufacturing and supply contracts around the world, including the United States, the United Kingdom, South Korea and Brazil, with the goal of producing more than 2 billion doses of experimental vaccine. Catalent Cell – Gene Therapy is a full service partner for ADENo-associated viral vectors (AAV) and CAR-T immunotherapies with deep experience in viral vector climbing and production. Catalent recently acquired MaSTherCell and has expertise in the development and manufacture of autogenic cell therapies to position Catalent as a leading technology, development and manufacturing partner for innovators in all advanced biotherapies. Catalent has a global network of clinical and commercial production sites, as well as finishing and filling packaging functions, located in the United States and Europe. Catalent Cell – Gene Therapy has produced more than 100 cGMP lots in more than 70 clinical and commercial programs. For more information, see biologics.catalent.com/cell-gene-therapy/ The candidate for a vector-based vaccine, AZD1222, was co-found by Oxford University and its spin-out company Vaccitech and was licensed by AstraZeneca. The vaccine candidate is currently in clinical trials. Catalent, Inc. (NYSE: CTLT) is the world leader in advanced delivery technologies, drug development and manufacturing solutions, biologics, cell and gene therapies, and consumer health products.

With more than 85 years at the service of the industry, Catalent has a proven track record of bringing more customer products to market faster, improving product performance and ensuring a reliable clinical and commercial supply of products globally. Catalent employs more than 13,500 people, including more than 2,400 scientists and technicians, at more than 40 sites and generated annual sales of more than $2.5 billion in fiscal 2019. Catalent is headquartered in Somerset, New Jersey. For more information, see www.catalent.com SOMERSET, N.J. – June 15, 2020 – Catalent, Inc. (NYSE: CTLT), the world`s leading provider of advanced delivery technologies, the development and production of drug solutions, Biologists, Cell and gene therapies and consumer health products, announced today that Catalent Biologics AstraZeneca PLC will provide bottling and packaging capabilities at the Catalent production site in Anagni, Italy, and prepare for the large-scale commercial supply of the candidate for the Adenovirus vector COVID-19 of Oxford University, AZD122.